Skip to main content
Clinical Trials/CTRI/2012/10/003065
CTRI/2012/10/003065
Completed
Phase 3

Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®. - PROTECT-2

Sandoz GmbH0 sites302 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Sandoz GmbH
Enrollment
302
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. histologically proven breast cancer
  • 2\. eligible for six cycles of neoadjuvant or adjuvant chemotherapy

Exclusion Criteria

  • 1\. History of cancer
  • 2\. Active infection
  • 3\. Known immunodeficiency syndrome
  • 4\. Previous therapy with any G\-CSF (granulocyte\-colony stimulating factor) product
  • Other protocol\-defined inclusion/exclusion criteria may apply.

Outcomes

Primary Outcomes

Not specified

Similar Trials